Blarcamesine hydrochloride 10 mg | 99.95%
TargetMol
Blarcamesine hydrochloride (AVex-73 hydrochloride) is a Sigma-1 Receptor agonist (IC50: 860 nM).
More Information Supplier PageBlarcamesine hydrochloride
Search Results
Goserelin acetate 5 mg | 100.00%
TargetMol
Goserelin acetate is a synthetic long-acting agonist of gonadotropin-releasing hormone, used in treatments of cancer.
More Information Supplier PageGoserelin acetate
Goserelin acetate 50 mg | 100.00%
TargetMol
Goserelin acetate is a synthetic long-acting agonist of gonadotropin-releasing hormone, used in treatments of cancer.
More Information Supplier PageGoserelin acetate
Goserelin acetate 10 mg | 100.00%
TargetMol
Goserelin acetate is a synthetic long-acting agonist of gonadotropin-releasing hormone, used in treatments of cancer.
More Information Supplier PageGoserelin acetate
S 38093 5 mg | 99.98%
TargetMol
S 38093 is a brain-penetrant antagonist of the H3 receptor (Ki: 8.8/1.44/1.2 μM, for rat/mouse/human).
More Information Supplier PageS 38093
S 38093 10 mg | 99.98%
TargetMol
S 38093 is a brain-penetrant antagonist of the H3 receptor (Ki: 8.8/1.44/1.2 μM, for rat/mouse/human).
More Information Supplier PageS 38093
LY2334737 5 mg | 99.40%
TargetMol
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
More Information Supplier PageLY2334737
LY2334737 50 mg | 99.40%
TargetMol
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
More Information Supplier PageLY2334737
LY2334737 25 mg | 99.40%
TargetMol
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
More Information Supplier PageLY2334737
LY2334737 10 mg | 99.40%
TargetMol
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
More Information Supplier PageLY2334737